GM103
Stage unconfirmedAn oncolytic adenovirus that induces tumour-specific immune responses and inhibits tumour angiogenesis, being prepared for a Phase 1 trial in metastatic lung and liver cancer.
A company developing oncolytic adenovirus gene therapies built on patented genetic-engineering technology.
An oncolytic adenovirus that induces tumour-specific immune responses and inhibits tumour angiogenesis, being prepared for a Phase 1 trial in metastatic lung and liver cancer.
Oncolytic adenovirus candidates the company showcased at a 2026 exhibition.
Selected for a 2026 Korea Drug Development Fund Phase 1 clinical development project.
Exhibited its GM101, GM102 and GM103 pipeline at KOREA LIFE SCIENCE WEEK 2026.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.